Processa Pharmaceuticals (PCSA) EBITDA Yield: History & Chart

Processa Pharmaceuticals, Inc.(PCSA)

Biotechnology · Vero Beach, FL

$1.49-0.00 (-0.34%)

Delayed quote: Oct 6, 2026, 3:27 PM EDT

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Vero Beach, FL

12 employees

www.processapharmaceuticals.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: George K. Ng

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Processa Pharmaceuticals, Inc. (PCSA)	$4.11M	N/A	N/A	N/A	N/A
GRI Bio, Inc. (GRI)vs ›	$4.13M	N/A	N/A	N/A	N/A
Aptevo Therapeutics Inc. (APVO)vs ›	$3.97M	N/A	N/A	N/A	N/A
CollPlant Biotechnologies Ltd. (CLGN)vs ›	$4.27M	N/A	2.09%	2.09%	2.09%
60 Degrees Pharmaceuticals, Inc. (SXTP)vs ›	$3.85M	N/A	N/A	N/A	N/A
20/20 Biolabs Inc. (AIDX)vs ›	$4.44M	N/A	N/A	N/A	N/A
Dermata Therapeutics, Inc. (DRMA)vs ›	$4.55M	N/A	N/A	N/A	N/A
Evogene Ltd. (EVGN)vs ›	$3.62M	N/A	N/A	N/A	N/A
Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs ›	$3.74M	N/A	N/A	N/A	N/A
Ernexa Therapeutics Inc. (ERNA)vs ›	$3.61M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Processa Pharmaceuticals, Inc. (PCSA)

$4.11M

N/A

GRI Bio, Inc. (GRI)vs ›

$4.13M

N/A

Aptevo Therapeutics Inc. (APVO)vs ›

$3.97M

N/A

CollPlant Biotechnologies Ltd. (CLGN)vs ›

$4.27M

N/A

2.09%

60 Degrees Pharmaceuticals, Inc. (SXTP)vs ›

$3.85M

N/A

20/20 Biolabs Inc. (AIDX)vs ›

$4.44M

N/A

Dermata Therapeutics, Inc. (DRMA)vs ›

$4.55M

N/A

Evogene Ltd. (EVGN)vs ›

$3.62M

N/A

Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs ›

$3.74M

N/A

Ernexa Therapeutics Inc. (ERNA)vs ›

$3.61M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

PCSA EBITDA Yield Metrics

PCSA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics